Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 95 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... June 11, 2025 Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... October 19, 2021 What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... November 1, 2021 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Load more HOT NEWS Welcome to our new committee chairs Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness... The Barriers to Care Faced by LGBTQ People With Cancer: An... As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s...
